InvestorsHub Logo
Followers 68
Posts 5584
Boards Moderated 0
Alias Born 01/13/2012

Re: Johny37939 post# 202345

Thursday, 10/24/2019 10:54:46 AM

Thursday, October 24, 2019 10:54:46 AM

Post# of 334371
Leadership, mentorship, wisdom, senior executive experience, diplomacy and regulatory and political dexterity are rarely found in men or women younger than mid-60's.

Such a CEO, and a refined gentleman to boot, leading a younger, motivated, BIEL team would constitute a Dream Team IMO. At the CEO levels, it's often who you know, recognition and earned credibility that opens doors widely and quickly.

My instincts lead me to think if Dr. Staelin were willing to help the potentially massive growth phase of BIEL at hand, it might be for a period of 24 to 36 months, maximum, plenty of time to get BIEL to many tens of millions in annual sales.

Feel strongly it's about informed professional demeanor and strong task assignment and completion, at the moment. Next phase could be more youthful, let's get the ship floating and moving forward first.

Given his approx. 8 1/2 years as BIEL Chair, during the regulatory ramp-up, and FDA leadership teamwork since 2017, just a thought, is Dr. Staelin a BIEL shareholder and if so, how substantial, anyone know? If he holds a large position, it would constitute a strong incentive, no?